Cargando…
Efficacy, safety, and economy of shensongyangxin capsules for the treatment of coronary heart disease arrhythmia: a meta-analysis of randomized controlled trials
BACKGROUND: Shensong Yangxin Capsules (SSYX) is a proprietary Chinese medicine commonly, used in the treatment of arrhythmia. In recent years, a flurry of randomized controlled trials of SSYX was reported in the treatment of Coronary heart disease arrhythmia in China. However, these experiments have...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10553141/ https://www.ncbi.nlm.nih.gov/pubmed/37811103 http://dx.doi.org/10.1097/MS9.0000000000001244 |
_version_ | 1785116101730893824 |
---|---|
author | Ma, Luyao Li, Libing Ma, Fujin Ma, Fuyun Ma, Shujia |
author_facet | Ma, Luyao Li, Libing Ma, Fujin Ma, Fuyun Ma, Shujia |
author_sort | Ma, Luyao |
collection | PubMed |
description | BACKGROUND: Shensong Yangxin Capsules (SSYX) is a proprietary Chinese medicine commonly, used in the treatment of arrhythmia. In recent years, a flurry of randomized controlled trials of SSYX was reported in the treatment of Coronary heart disease arrhythmia in China. However, these experiments have not been systematically evaluated by economics. The purpose of this study was to assess the efficacy, safety, and economy of the SSYX in the treatment of arrhythmia in patients with coronary heart disease. METHODS: With “Shensong Yangxin Capsules” “Coronary Heart Disease” “Coronary Atherosclerotic Heart Disease”and “Arrhythmia” as the subject words, the relevant journals and conference papers were searched manually in China National Knowledge Infrastructure (CNKI), Wanfang Database, VIP, PubMed, Web Of Science, CBM, Embase and The Cochrane Library. The literature of randomized controlled trials of SSYX in the treatment of coronary heart disease arrhythmia was searched until November 2022. All data were analyzed using RevMan 5.3 Sotware and combined with cost-effectiveness for economic evaluation. RESULTS: Twenty randomized controlled trials were included in this study, with a total of 2011 cases. The meta-analysis showed that the therapeutic effect of SSYX-metoprolol is superior to that of metoprolol alone. SSYX is superior to amiodarone in improving the total clinical effective rate, reducing the incidence of adverse reactions, and reducing the junction premature beats. There was no significant difference between the SSYX and amiodarone in the curative effect of ECG, ventricular premature complexes, and atrial premature beats. The results of pharmacoeconomics show that SSYX has a cost-effectiveness advantage in treating coronary heart disease arrhythmia. Single-factor sensitivity analysis also confirmed the stability of the results. In summary, SSYX has a curative effect, safety, and economy in treating coronary heart disease arrhythmia. |
format | Online Article Text |
id | pubmed-10553141 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Lippincott Williams & Wilkins |
record_format | MEDLINE/PubMed |
spelling | pubmed-105531412023-10-06 Efficacy, safety, and economy of shensongyangxin capsules for the treatment of coronary heart disease arrhythmia: a meta-analysis of randomized controlled trials Ma, Luyao Li, Libing Ma, Fujin Ma, Fuyun Ma, Shujia Ann Med Surg (Lond) Reviews BACKGROUND: Shensong Yangxin Capsules (SSYX) is a proprietary Chinese medicine commonly, used in the treatment of arrhythmia. In recent years, a flurry of randomized controlled trials of SSYX was reported in the treatment of Coronary heart disease arrhythmia in China. However, these experiments have not been systematically evaluated by economics. The purpose of this study was to assess the efficacy, safety, and economy of the SSYX in the treatment of arrhythmia in patients with coronary heart disease. METHODS: With “Shensong Yangxin Capsules” “Coronary Heart Disease” “Coronary Atherosclerotic Heart Disease”and “Arrhythmia” as the subject words, the relevant journals and conference papers were searched manually in China National Knowledge Infrastructure (CNKI), Wanfang Database, VIP, PubMed, Web Of Science, CBM, Embase and The Cochrane Library. The literature of randomized controlled trials of SSYX in the treatment of coronary heart disease arrhythmia was searched until November 2022. All data were analyzed using RevMan 5.3 Sotware and combined with cost-effectiveness for economic evaluation. RESULTS: Twenty randomized controlled trials were included in this study, with a total of 2011 cases. The meta-analysis showed that the therapeutic effect of SSYX-metoprolol is superior to that of metoprolol alone. SSYX is superior to amiodarone in improving the total clinical effective rate, reducing the incidence of adverse reactions, and reducing the junction premature beats. There was no significant difference between the SSYX and amiodarone in the curative effect of ECG, ventricular premature complexes, and atrial premature beats. The results of pharmacoeconomics show that SSYX has a cost-effectiveness advantage in treating coronary heart disease arrhythmia. Single-factor sensitivity analysis also confirmed the stability of the results. In summary, SSYX has a curative effect, safety, and economy in treating coronary heart disease arrhythmia. Lippincott Williams & Wilkins 2023-09-01 /pmc/articles/PMC10553141/ /pubmed/37811103 http://dx.doi.org/10.1097/MS9.0000000000001244 Text en Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) |
spellingShingle | Reviews Ma, Luyao Li, Libing Ma, Fujin Ma, Fuyun Ma, Shujia Efficacy, safety, and economy of shensongyangxin capsules for the treatment of coronary heart disease arrhythmia: a meta-analysis of randomized controlled trials |
title | Efficacy, safety, and economy of shensongyangxin capsules for the treatment of coronary heart disease arrhythmia: a meta-analysis of randomized controlled trials |
title_full | Efficacy, safety, and economy of shensongyangxin capsules for the treatment of coronary heart disease arrhythmia: a meta-analysis of randomized controlled trials |
title_fullStr | Efficacy, safety, and economy of shensongyangxin capsules for the treatment of coronary heart disease arrhythmia: a meta-analysis of randomized controlled trials |
title_full_unstemmed | Efficacy, safety, and economy of shensongyangxin capsules for the treatment of coronary heart disease arrhythmia: a meta-analysis of randomized controlled trials |
title_short | Efficacy, safety, and economy of shensongyangxin capsules for the treatment of coronary heart disease arrhythmia: a meta-analysis of randomized controlled trials |
title_sort | efficacy, safety, and economy of shensongyangxin capsules for the treatment of coronary heart disease arrhythmia: a meta-analysis of randomized controlled trials |
topic | Reviews |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10553141/ https://www.ncbi.nlm.nih.gov/pubmed/37811103 http://dx.doi.org/10.1097/MS9.0000000000001244 |
work_keys_str_mv | AT maluyao efficacysafetyandeconomyofshensongyangxincapsulesforthetreatmentofcoronaryheartdiseasearrhythmiaametaanalysisofrandomizedcontrolledtrials AT lilibing efficacysafetyandeconomyofshensongyangxincapsulesforthetreatmentofcoronaryheartdiseasearrhythmiaametaanalysisofrandomizedcontrolledtrials AT mafujin efficacysafetyandeconomyofshensongyangxincapsulesforthetreatmentofcoronaryheartdiseasearrhythmiaametaanalysisofrandomizedcontrolledtrials AT mafuyun efficacysafetyandeconomyofshensongyangxincapsulesforthetreatmentofcoronaryheartdiseasearrhythmiaametaanalysisofrandomizedcontrolledtrials AT mashujia efficacysafetyandeconomyofshensongyangxincapsulesforthetreatmentofcoronaryheartdiseasearrhythmiaametaanalysisofrandomizedcontrolledtrials |